SiBone (SIBN) to Release Quarterly Earnings on Monday

SiBone (NASDAQ:SIBN) is expected to be releasing its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect SiBone to post earnings of ($0.13) per share and revenue of $56.2610 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 4:30 PM ET.

SiBone Stock Up 2.3%

SIBN opened at $15.33 on Monday. SiBone has a one year low of $12.49 and a one year high of $21.89. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The stock’s fifty day moving average is $18.18 and its 200-day moving average is $16.89. The company has a market capitalization of $665.17 million, a PE ratio of -30.06 and a beta of 0.69.

Insiders Place Their Bets

In other news, CEO Laura Francis sold 5,411 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $17.70, for a total value of $95,774.70. Following the completion of the sale, the chief executive officer owned 351,319 shares in the company, valued at $6,218,346.30. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Anshul Maheshwari sold 18,542 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $20.15, for a total value of $373,621.30. Following the completion of the sale, the chief financial officer directly owned 185,231 shares of the company’s stock, valued at approximately $3,732,404.65. This trade represents a 9.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 97,956 shares of company stock valued at $1,958,807 over the last 90 days. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On SiBone

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its stake in SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. State of Wyoming acquired a new stake in shares of SiBone during the second quarter worth approximately $55,000. Canada Pension Plan Investment Board acquired a new stake in shares of SiBone during the second quarter worth approximately $68,000. Quarry LP grew its position in SiBone by 862.6% during the third quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after purchasing an additional 4,356 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in SiBone by 1,443.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,305 shares of the company’s stock valued at $85,000 after buying an additional 4,026 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SIBN. TD Cowen upgraded shares of SiBone to a “strong-buy” rating in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Morgan Stanley increased their target price on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC raised their target price on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Truist Financial lifted their price target on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.33.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.